Compositions Useful for Reducing Toxicity Associated with Gadolinium-based Contrast Agents
AssigneeVerrow Pharmaceuticals, Inc.
InventorVernon D. Rowe
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions comprising a gadolinium-based contrast agent and a derivatized cyclodextrin. Further provided are methods for reducing the toxicity associated with gadolinium-based contrast agents.
Claims25
A composition comprising a gadolinium-based contrast agent and a derivatized cyclodextrin wherein
- the molar ratio of said agent to said cyclodextrin is greater than 1:1;
- and wherein
- said cyclodextrin is of the formula:
- cyclodextrin-[(O—R—Y)−(Me)+]n
- where R is selected from the group consisting of straight-chained or branched C1-10 alkyl, alkenyl or alkynyl;
- C3-8 cycloalkyl and C3-8 aryl, each ring optionally containing 1 or more heteroatoms selected from S, N and O;
- and optionally substituted with halo or hydroxyl;
- Y is an anionic group selected from the group consisting of COO, SO4, SO3, PO3H and PO4;
- Me is a pharmaceutically acceptable cation;
- and
- n is a number greater than or equal to 1.
A composition comprising a gadolinium-based contrast agent and a derivatized cyclodextrin wherein
- the molar ratio of said agent to said cyclodextrin is greater than 1:1;
- and wherein
- said cyclodextrin is of the formula:
- cyclodextrin-[O—R]n
- where R is selected from the group consisting of straight-chained or branched C1-10 alkyl, alkenyl or alkynyl;
- C3-8 cycloalkyl and C3-8 aryl, each ring optionally containing 1 or more heteroatoms selected from S, N and O;
- and R is substituted with one or more hydroxyl groups;
- and
- n is a number greater than or equal to 1.
A method of inhibiting or reducing toxicity associated with a gadolinium-based contrast agent, the method comprising concurrently administering to a subject a pharmaceutical composition comprising a gadolinium-based contrast agent and a pharmaceutical composition comprising a derivatized cyclodextrin;
- wherein the administered molar amount of said agent is greater than the administered molar amount of said cyclodextrin.
A kit comprising two separate containers wherein the first container holds a gadolinium-based contrast agent formulation for injection and the second container holds a derivatized cyclodextrin formulation for injection.
Dependencies are inferred from the claim text.